PLoS ONE (Jan 2014)

Clinical and biochemical function of polymorphic NR0B1 GGAA-microsatellites in Ewing sarcoma: a report from the Children's Oncology Group.

  • Michael J Monument,
  • Kirsten M Johnson,
  • Elizabeth McIlvaine,
  • Lisa Abegglen,
  • W Scott Watkins,
  • Lynn B Jorde,
  • Richard B Womer,
  • Natalie Beeler,
  • Laura Monovich,
  • Elizabeth R Lawlor,
  • Julia A Bridge,
  • Joshua D Schiffman,
  • Mark D Krailo,
  • R Lor Randall,
  • Stephen L Lessnick

DOI
https://doi.org/10.1371/journal.pone.0104378
Journal volume & issue
Vol. 9, no. 8
p. e104378

Abstract

Read online

The genetics involved in Ewing sarcoma susceptibility and prognosis are poorly understood. EWS/FLI and related EWS/ETS chimeras upregulate numerous gene targets via promoter-based GGAA-microsatellite response elements. These microsatellites are highly polymorphic in humans, and preliminary evidence suggests EWS/FLI-mediated gene expression is highly dependent on the number of GGAA motifs within the microsatellite.Here we sought to examine the polymorphic spectrum of a GGAA-microsatellite within the NR0B1 promoter (a critical EWS/FLI target) in primary Ewing sarcoma tumors, and characterize how this polymorphism influences gene expression and clinical outcomes.A complex, bimodal pattern of EWS/FLI-mediated gene expression was observed across a wide range of GGAA motifs, with maximal expression observed in constructs containing 20-26 GGAA motifs. Relative to white European and African controls, the NR0B1 GGAA-microsatellite in tumor cells demonstrated a strong bias for haplotypes containing 21-25 GGAA motifs suggesting a relationship between microsatellite function and disease susceptibility. This selection bias was not a product of microsatellite instability in tumor samples, nor was there a correlation between NR0B1 GGAA-microsatellite polymorphisms and survival outcomes.These data suggest that GGAA-microsatellite polymorphisms observed in human populations modulate EWS/FLI-mediated gene expression and may influence disease susceptibility in Ewing sarcoma.